Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 8, Pages 1198
Publisher
MDPI AG
Online
2019-08-19
DOI
10.3390/cancers11081198
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma
- (2018) Jakub Svoboda et al. BLOOD
- Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials
- (2018) Fatemeh Arabi et al. EXPERIMENTAL CELL RESEARCH
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
- (2018) Jan Dörrie et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Markers for human brain pericytes and smooth muscle cells
- (2018) Leon C.D. Smyth et al. JOURNAL OF CHEMICAL NEUROANATOMY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy
- (2018) Serena Pellegatta et al. Science Translational Medicine
- Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
- (2018) Kristina M. Ilieva et al. Frontiers in Immunology
- Standardizing CAR-T therapy: Getting it scaled up
- (2018) Xiaofeng Dai et al. BIOTECHNOLOGY ADVANCES
- Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
- (2017) Zhenguang Wang et al. Protein & Cell
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- The Role of NG2 Proteoglycan in Glioma
- (2016) Sridevi Yadavilli et al. Translational Oncology
- Clinical manufacturing of CAR T cells: foundation of a promising therapy
- (2016) Xiuyan Wang et al. Molecular Therapy-Oncolytics
- Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone
- (2015) Christian Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors
- (2015) Yangyang Wang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
- (2015) Pier Andrea Nicolosi et al. Theranostics
- A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor
- (2014) Christian Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues
- (2014) Hannes Brehm et al. CANCER LETTERS
- Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
- (2014) Rachel E Beard et al. Journal for ImmunoTherapy of Cancer
- Chimeric Antigen Receptor Therapy for Cancer
- (2013) David M. Barrett et al. Annual Review of Medicine
- T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
- (2013) C. Geldres et al. CLINICAL CANCER RESEARCH
- Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
- (2013) Michael Kalos et al. IMMUNITY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- Cell-based Flow Cytometry Assay to Measure Cytotoxic Activity
- (2013) Alessandra Noto et al. Jove-Journal of Visualized Experiments
- Eradication of melanomas by targeted elimination of a minor subset of tumor cells
- (2011) P. Schmidt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A High Molecular Weight Melanoma-Associated Antigen-Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- (2010) W. R. Burns et al. CANCER RESEARCH
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
- (2010) Xinhui Wang et al. JNCI-Journal of the National Cancer Institute
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
- (2010) Marco de Bruyn et al. Molecular Cancer
- Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer
- (2009) K Birkholz et al. GENE THERAPY
- A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells
- (2009) Michael Schwenkert et al. MELANOMA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started